Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

アキレスの破裂

T Fest, J L Dupond

    Lancet (London, England)
    |October 14, 1989
    PubMed
    まとめ

    No abstract available in PubMed .

    関連する実験動画

    関連する概念動画

    こちらも読む

    関連記事

    共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

    並び替え
    Same author

    Minimal residual disease detection in Tunisian B-acute lymphoblastic leukemia based on immunoglobulin gene rearrangements.

    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2017
    Same author

    Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients.

    Leukemia·2016
    Same author

    Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients.

    Annals of oncology : official journal of the European Society for Medical Oncology·2014
    Same author

    High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.

    Leukemia·2014
    Same author

    IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors.

    Leukemia·2014
    Same author

    Cyclophosphamide as a first-line therapy in LGL leukemia.

    Leukemia·2013
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    Same journal

    Dual mobility total hip replacement in fractures: stability promotes patient confidence.

    Lancet (London, England)·2026
    Same journal

    Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

    Lancet (London, England)·2026
    関連記事をすべて見る